ReviewBlood science (Baltimore, Md.)2026
Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system.
Review in Blood science (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has transformed hematologic cancer treatment; however, its application in patients with central nervous system (CNS) involvement remains challenging because of exclusion from key trials. Recent data show that CAR-T cells can breach the blood-brain barrier (BBB) and achieve clinically significant responses in CNS lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). However, limited CNS trafficking, antigen escape, an immunosuppressive microenvironment, and treatment-related neurotoxicity constrain therapeutic efficacy. This review synthesizes recent clinical outcomes, elucidates mechanisms of CNS infiltration and neurotoxicity, and evaluates emerging strategies, including optimized CAR designs, BBB-modulating technologies, alternative delivery routes, and rational combination therapies, to enhance safety and efficacy. Disease-specific nuances, such as Parkinson-like symptoms in CNS myeloma and differential neurotoxicity profiles between primary and secondary CNS lymphomas, are highlighted. By identifying key knowledge gaps and proposing prioritized research directions, this study aims to guide the future translation of CAR-T therapy for CNS hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.